BioMarin Pharmaceutical (BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions. This stock is trading up 1.1% to $36.00 in recent trading after hitting a 52-week high of $36.13 earlier in the day.
Today's Range: $35.47-$36.1352-Week Range: $23.09-$35.94 Volume: 225,000 Three-Month Average Volume: 803,464 BioMarin Pharmaceutical has a market cap of $4.11 billion and an enterprise value of $4.19 billion. This stock trades at a price-to-sales of 9.34 and a price-to-book of 5.25. Its estimated growth rate for this year is -120.2%, and for next year it's pegged at 8.6%. The current short interest as a percentage of the float for BioMarin Pharmaceutical is notable at 6.8%. From a technical standpoint, BMRN has started to trigger a major breakout trade today now that the stock is taking out some past overhead resistance at $35.47 to $35.56. The only thing lacking on this breakout is heavy volume, since only 225,000 shares have traded versus its average volume of 803,463. That said, price always trumps volume, so if BMRN can sustain a move and close over $35.56, then it has a shot at trading back toward its all-time high at $40. Traders should continue to monitor the volume in the coming days to see if it firms up, and continue to look for long-biased trades as long as BMRN continues its trend above $35.47 to $35.56. As of the most recently reported quarter, BioMarin is one of the top holdings in Columbia Wanger Asset Management's portfolio.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV